about
Molecular motors implicated in the axonal transport of tau and alpha-synucleinAlzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss.Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathwayCritical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease.Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau.Dynamic association of tau with neuronal membranes is regulated by phosphorylation.Loss of c-Jun N-terminal kinase-interacting protein-1 does not affect axonal transport of the amyloid precursor protein or Aβ production.Roles of tau protein in health and disease.Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivoα-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP productionCalsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates Aβ productionCalpain cleavage and inactivation of the sodium calcium exchanger-3 occur downstream of Aβ in Alzheimer's disease.Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture.Advances in tau-based drug discovery.Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease.Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain.Prostate-derived sterile 20-like kinases (PSKs/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease.The importance of tau phosphorylation for neurodegenerative diseasesTau phosphorylation: the therapeutic challenge for neurodegenerative disease.The microtubule-associated protein tau is also phosphorylated on tyrosine.Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease.Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures.Functional implications of glycogen synthase kinase-3-mediated tau phosphorylationNeurodegeneration as an RNA disorder.A role for tau at the synapse in Alzheimer's disease pathogenesis.Intracellular and extracellular roles for tau in neurodegenerative disease.Physiological release of endogenous tau is stimulated by neuronal activity.Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.ALS/FTD-associated FUS activates GSK-3β to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations.Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer's diseaseChallenges in neurodegeneration research.Anti-inflammatory impact of minocycline in a mouse model of tauopathy.Tau phosphorylation affects its axonal transport and degradation.The ER-Mitochondria Tethering Complex VAPB-PTPIP51 Regulates Autophagy.Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate.Evidence that the presynaptic vesicle protein CSPalpha is a key player in synaptic degeneration and protection in Alzheimer's disease.Linking amyloid and tau pathology in Alzheimer's disease: the role of membrane cholesterol in Abeta-mediated tau toxicity.Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques.Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease.Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression.
P50
Q24336019-56665EFC-0012-434A-88FB-2172EA899CA2Q27303472-6D7E12CB-29DE-4B9E-86A6-E47512EF1B2EQ29870999-5FD412C0-B52D-4BCC-B2F7-A8CFD2D7E5A8Q30008912-388D7342-8A6B-4C8A-84E7-4A79AADB53A5Q30010481-DBE48258-D8BC-4040-95F7-6CD08BA23ECDQ30155626-41845C2D-C63C-40D3-92B7-CA21409024E5Q30564134-57363F11-FD0D-4444-B8ED-A8761BDA3923Q33559303-9920CB83-30A8-43F8-8D23-AA1117B73060Q33771431-90838340-2559-49CF-89A4-56E576194B82Q33841149-9FF418D1-B427-4FC1-A21C-1A6EAF9487E6Q34262615-145188F7-0D39-4E90-9AC6-AB7BDB40D883Q35080456-E914BAA9-6E6F-484E-BEAD-EF30A7019EBAQ35202286-9F08B9A6-F237-444C-9432-56D8BBA3724FQ35321539-3DF98E59-0A96-482F-ACCF-A0C154A82B7AQ36295178-38B6206E-CC5E-4731-8885-1142EBCA73D0Q36758446-6DC44616-7E06-4F92-8AA5-CD5DE43752BAQ36873750-8277F34A-BB4D-4DED-B947-357893D97303Q36968220-6DA6BA1E-BFDA-404C-92BD-11B7C0D72965Q37402114-8334C716-68BB-4931-AA1A-23FF89D30F01Q37525953-30FD2206-615E-4F9E-A63F-A8AACE8FC4A3Q37630546-08B131C4-9699-4EFD-9B3F-E71C82209482Q37745627-9F00DB6C-65F5-4653-866E-4EDD9AC9130CQ37903257-E5506F39-4C38-406D-8DD8-5F63AEA9EE57Q38051910-37206C0F-0FD1-4E3E-8579-EBCDC5FDC756Q38146417-ACFB03B8-2FC2-40AC-8415-32E647A9AA99Q38193310-E733F16D-C5BA-4828-A55E-D866358828B6Q39560268-86B69E85-2155-4131-A9C4-4C3BED70AC55Q40398116-8DC89D66-6AFD-41A2-BFA8-31638085712EQ40991422-CFA4161A-1F6F-4E50-BA5E-C4A2393EB28DQ41286854-FD36A363-A8DA-4D54-BA0C-E4048E86B447Q41809126-0CD405D1-CD54-4B07-82FF-AF32C78CE30DQ41854166-C92E6187-9C50-4AC9-B24B-3C649DB2014AQ42160128-3693F2B8-4434-4893-BF42-A5292A95D9CBQ42253285-943C1059-E90D-48DB-A96D-1227BFE01631Q42407159-4030F4DA-D087-44AC-8A39-767AFF9B7E33Q43128335-8DB79643-537D-4AD2-B09D-E19A9EC9AED4Q43298118-7612D412-F629-4E9E-B33F-3C6FCFFB1A92Q44306302-6CDB2F0C-6FF4-4A6C-9743-A4E5A21FFC93Q46252934-36FEDE15-2698-4BC0-B880-6F6FC280BAA0Q47597706-D36E5C16-87AB-4850-AF36-B6641B0600BB
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Wendy Noble
@ast
Wendy Noble
@en
Wendy Noble
@es
Wendy Noble
@nl
Wendy Noble
@sl
type
label
Wendy Noble
@ast
Wendy Noble
@en
Wendy Noble
@es
Wendy Noble
@nl
Wendy Noble
@sl
altLabel
Wendy Jane Noble
@en
prefLabel
Wendy Noble
@ast
Wendy Noble
@en
Wendy Noble
@es
Wendy Noble
@nl
Wendy Noble
@sl
P1053
C-3756-2009
P106
P1153
7102481785
P21
P31
P3829
P496
0000-0002-7898-4295
P569
2000-01-01T00:00:00Z